Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125136 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL28008648 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL28008331 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8430064 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8846918 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL30680466 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27432548 | 0.94 | KMT2A (0.57) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17138157 | 0.91 | KMT2A (0.54) | LMNAKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL7980728 | 0.91 | LMNA (0.65) | LMNAKMT2ASMN1; SMN2GAAACHE | |
| SCHEMBL9736780 | 0.91 | LMNA (0.65) | LMNAKMT2ASMN1; SMN2GAAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012017204-A1 | EFFICIENT AND COST-EFFECTIVE PROCESS FOR THE MANUFACTURE OF AMYL M-CRESOL | AESICA PHARMACEUTICALS LIMITED (GB) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017204-A1 | EFFICIENT AND COST-EFFECTIVE PROCESS FOR THE MANUFACTURE OF AMYL M-CRESOL | AESICA PHARMACEUTICALS LIMITED (GB) | 2012-02-09 | — | — | WO | disclosed |
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2316831-A1 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| EP-0950669-B1 | Method of catalytic crosslinking of polymers and two-pack composition used therein | ROHM & HAAS (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6306991-B1 | TWO PART COATING COMPOSITION WITH TWO CONTAINERS, OXIDATIVE POLYMERS WITH CROSSLINKABLE FUNCTIONAL GROUPS | ROHM AND HAAS COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6149977-A | CONTACTING THE OXIDATIVE POLYMER WITH A CATALYTIC AMOUNT OF AN OXIDIZING ENZYME, SUCH AS HORSERADISH PEROXIDASE. | ROHM AND HAAS COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0950669-A2 | Method of catalytic crosslinking of polymers and two-pack composition used therein | ROHM AND HAAS COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KB, AKT3, PI4KA | LMNA 2754/4885KMT2A 2719/4885ALDH1A1 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.